Stock Analiz

Rigel Pharmaceuticals Inc. RIGL

Biotechnology: Pharmaceutical Preparations · IPO 2000 · data as of November 13, 2026

$44.46Market cap $837M
Open the interactive analysis →

Rigel Pharmaceuticals Inc. (RIGL) is a healthcare company listed in the US with a market value of about $837M. In the twelve months to September 30, 2026 it had revenue of $288M and net income of $307M, a net margin of 106.6%.

Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).

Key numbers: a P/E of 2.8, a price to free cash flow of 43.2, 5-year revenue growth of 22% a year, a 5-year average ROIC of -35%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% above the current price.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2000. Revenue went from $20M in 2016 to $294M in 2025, growth of about 34.5% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 11% over three years (dilution for shareholders). It spends 11% of revenue on research and development.

Score: 3.0 / 5

Value3/5
Future growth4/5
Track record2/5
Financial health5/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year

Checks not passed

  • P/FCF below 20
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • Pays a dividend
  • Share count down over 3 years (buybacks)

Valuation

P/E (TTM)2.8
Forward P/E11.1
P/FCF43.2
P/S2.9
P/B1.9
EV/EBITDA9.4
PEG—
Dividend yield0.00%
FCF yield2.3%
Shareholder yield0.0%
Intrinsic value vs. price+60%

Growth and quality

Revenue growth (1 yr)64.1%
Revenue growth (5 yrs, per year)22.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)10.5%
ROIC (5-yr avg.)-35.0%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$288M$294M$179M$117M$120M$149M$109M$59M$45M$4M$20M
Net income$307M$367M$17M-$25M-$59M-$18M-$30M-$67M-$70M-$78M-$69M
Free cash flow$19M———-$74M$5M-$53M-$43M-$60M-$78M-$77M
EPS (diluted)$16.07$19.48$0.99$-1.44$-3.44$-1.11$-1.82$-4.04$-4.45$-6.27$-7.38
Net margin106.6%124.7%9.8%-21.5%-48.7%-12.0%-27.4%-112.8%-158.3%-1739.3%-339.6%
ROIC—22.3%36.2%-63.4%-154.0%-16.2%-31.2%-60.1%-52.3%-62.5%-100.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $64.40, 45% above the current price; targets range from $47.00 to $86.00; the consensus rating is “Buy”; expected EPS is $3.34 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Rigel Pharmaceuticals’s P/E ratio?

About 2.8, based on the last twelve months of diluted earnings per share (forward P/E about 11.1).

Is Rigel Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 60% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Rigel Pharmaceuticals pay a dividend?

Not currently.

Is Rigel Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Rigel Pharmaceuticals scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.